The Cuban vaccine against COVID-19 Abdala has been approved for use in children over 5 years of age in Mexico.
Although the opinion of the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) of Mexico, which authorizes its use in children over 5 years of age, dates from the end of May, it is now when the news jumps to the media of both countries then of the announcement this Monday of BioCubaFarma.
“After a rigorous evaluation process of the Cuban anticovid-19 vaccine, #Abdala receives approval from the Mexican Regulatory Authority Cofepris, to be used in pediatric ages from 5 years of age,” the Business Group of the Biotechnological and Pharmaceutical Industries of Cuba.
Last February it had transpired that Abdala’s application failed as a reinforcement option in Mexicoafter only one percent of the population chose to get the dose.
In the Mexican capital, where the Cuban drug was offered as the only option, not even 2,500 doses per day were administered between December 21, 2022 and January 24, 2023.
In contrast to these figures, in April of last year, when the first booster doses of other vaccines were applied, 82% of the population over 18 years of age (almost 6 million people) went to health centers to get it, but with the Cuban variant, only 84,515 requested it, which represents 1.1% of adults in the city.
The distrust in the vaccine developed by Cuba lies in the fact that it does not have the endorsement of the World Health Organization (WHO) and its effectiveness would only be proven against the original virus and not against dangerous variants such as omicron.
Abdala’s Lots They were bought by Mexico in November and last December, after several announcements by López Obrador about the acquisition.
In September, the Mexican government announced the signing of an agreement with Cuba for the purchase of nine million doses of Abdala.
